Does the PI3K pathway play a role in basal breast cancer?

Clinical Breast Cancer

Volumn 10, Issue SUPPL. 3, 2010, Pages

  Moulder, Stacy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

HER2; Targeted therapy; Triple negative disease

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; CAL 101; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; GSK 1059615; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 2206; NAVELBINE; NVP BGT 226; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; TEMSIROLIMUS; TRASTUZUMAB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOADING DRUG DOSE; LUNG FIBROSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREATITIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 78649717890     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.s.014     Document Type: Article

References (67)

1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34.
2. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638-45.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-23.
5. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76.
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-74
7. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9:R65.
8. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236-40.
9. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8:235-44.
10. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004; 6:219-24.
11. Gillham H, Golding MC, Pepperkok R, et al. Intracellular movement of green fluorescent protein-tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling. J Cell Biol 1999; 146:869-80.
12. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010; 5: 29-57.
13. Geering B, Cutillas PR, Nock G, et al. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 2007; 104:7809-14.
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
15. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phos-phorylation in breast cancer. Nat Med 2002; 8:1136-44.
16. Motti ML, Califano D, Troncone G, et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 2005; 166:737-49.
17. Lu S, Ren C, Liu Y, et al. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol 2006; 28:245-51.
18. Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinase switching between life and death. Pharmacol Res 2004; 50:545-9.
19. Vander Haar E, Lee SI, Bandhakavi S, et al. Insulin signaling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9:316-23.
20. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002; 4:648-57.
21. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
22. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772-5.
23. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005; 102:802-7.
24. Perren A, Weng L P, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155:1253-60.
25. Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005; 68:398-404.
26. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22.
27. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27:4536-41.
28. Carpenter J T, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23(16 suppl):19s (abstract 564).
29. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoad-juvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27:2630-7.
30. Morrow P, Wulf GM, Booser DJ, et al. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. J Clin Oncol 2010; 28(15 suppl):117s (abstract 1014).
31. Dieras VG, Gianni L, Jerusalem A, et al. Phase I clinical trial of everolimus (E) in combination with vinorelbine (V) and trastuzumab (H) in patients with HER2-positive (HER2+) metastatic breast cancer (MBC) with prior resistance to trastuzumab. Presented at: the 2009 American Society of Clinical Oncology Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA. Abstract 253.
32. Dalenc F, Campone P, Hupperets R, et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multi-center phase II clinical trial. J Clin Oncol 2010; 28(15 suppl):117s (abstract 1013).
33. Brachmann S, Fritsch C, Maira SM, et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009; 21:194-8
34. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51:5522-32.
35. Herman SE, Gordon AL, Wagner AJ, et al. The phosphatidylinositol 3-kinase-{delta} inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116:2078-88.
36. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mam-malian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63.
37. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68:206-15.
38. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022-30.
39. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64:4394-9.
40. Hoffman K, Holmes FA, Fraschini G, et al. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 1996; 37:254-8.
41. Kondapaka SB, Singh SS, Dasmahapatra G P, et al. Perifosine, a novel alkyl phos-pholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2:1093-103.
42. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007; 13:7421-31.
43. Leighl NB, Dent S, Clemons M, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008; 108:87-92.
44. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res 2008; 14: 618.
45. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and non basal subtypes. Clin Cancer Res 2009; 15:2302-10.
46. Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20:862-7.
47. Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of che-mosensitivity and outcome among triple-negative breast cancer. Oncol Rep 2009; 21:413-7.
48. Wang X, McCullough KD, Franke T F, et al. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 2000; 275:14624-31.
49. Sarkar S, Mazumdar A, Dash R, et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010; 9:592-603.
50. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27.
51. Sartor C, Zhou H, Perou C, et al. Basal-like breast cancer tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Breast Cancer Res Treat 2004; 88 (abstract 311).
52. Umemura S, Yoshida S, Ohta Y, et al. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007; 98:1889-92.
53. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10:1013-23.
54. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10:R101.
55. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68:6084-91.
56. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126:1121-31.
57. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40:102-7.
58. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26(15 suppl):43s (abstract 1009).
59. O'Shaughnessy J, Weckstein D, Vukelja S, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Presented at: the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 308.
60. Carey L, O'Shaughnessy J, O'Shaughnessy K, et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials. Cancer Res 2009; 69(24 suppl): (abstract 2014).
61. O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16:3523-5.
62. Pantuck AJ, Zeng G, Belldegrun AS, et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9:4641-52.
63. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66:5549-54.
64. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64:830-5.
65. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69:565-72.
66. Hoeflich K P, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009; 15:4649-64.
67. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009; 15:842-4.